Immunoreactive trypsin screening for cystic fibrosis

Area of Science:

• Biochemistry
• Pediatrics
• Neonatal screening

Background:

• Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
• Early detection of CF is crucial for timely intervention and improved outcomes.
• Neonatal screening programs aim to identify infants with CF shortly after birth.

Purpose of the Study:

• To evaluate the effectiveness of immunoreactive cationic trypsin (irCT) as a biomarker for neonatal screening of Cystic Fibrosis.
• To determine the sensitivity and specificity of the irCT test in a cohort of infants.

Main Methods:

• Radioimmunoassay was used to measure irCT levels in dried blood spot samples from 22 infants with CF and 132 control infants.
• Blood samples were collected around the 5th day of life, similar to standard newborn screening procedures.
• A cut-off limit of 100 micrograms/L was established based on mean + 3 SD for control infants.

Main Results:

• The mean irCT level in control infants was 42 +/- 19 micrograms/L.
• Sixteen out of 22 CF infants (73%) had irCT levels above the cut-off.
• The test demonstrated 99% specificity but only 73% sensitivity, with a high noise:signal ratio (30:1).

Conclusions:

• The irCT test exhibits high specificity but insufficient sensitivity for reliable neonatal CF screening.
• The observed false-negative rate suggests this method may not be optimal for widespread use in newborn CF detection.
• Further research into more sensitive and specific biomarkers is warranted for neonatal CF screening.